Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:16:05.028Z.
Calculation as of: 2026-10-06T16:16:05.028Z.
Quote observation: 2026-10-06T16:15:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: efaaa36d31f915a5dffaa91b800fc30e2d7f64892a7236e7a1e7b68ff3f7d584
PEG RATIO
N/A
Crescent Biopharma, Inc.
Market Cap
$522.99M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $522.99M | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $524.44M | N/A |
| Altimmune, Inc. (ALT)vs › | $521.19M | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $533.68M | N/A |
| 908 Devices Inc. (MASS)vs › | $509.02M | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $540.26M | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.93M | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.17M | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $550.37M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
